Hualan Biological Engineering Inc. researches, develops, produces, and commercializes blood products, vaccines, and genetic engineering products in China and internationally. The company offers human serum albumin to treat blood loss trauma, shock caused by burns, intracranial pressure and persistent, liver cirrhosis, and kidney disease; edema for hypoproteinemia, neonatal hyperbilirubinemia, cardiopulmonary bypass, adjuvant treatment of burns, hemodialysis, and human respiratory distress syndrome; intravenous human immunoglobulin (pH4) for immunoglobulin deficiency and autoimmune diseases; and human immunoglobulin to prevent measles and infectious hepatitis. It also provides hepatitis b human immunoglobulin to prevent hepatitis; immunoglobulin for rabies patients; human tetanus immune globulin for tetanus; human coagulation factor blood for bleeding symptoms; human prothrombin complex for congenital and acquired coagulation factor II, VH, IX, X deficiency, overdose of anticoagulants, vitamin k deficiency, bleeding, and hemophilia; and human fibrinogen for congenital fibrinogen reduction, and liver damage and cirrhosis, disseminated intravascular coagulation, postpartum hemorrhage, and coagulation disorders. In addition, the company offers human fibrin glue to treat local; freeze-dried human thrombin for bleeding from abdominal incision wounds; influenza virus split vaccine to prevent influenza; influenza A (H1N1) split vaccine for the prevention of influenza epidemics; ACYW135 group meningococcal polysaccharide vaccine to prevent epidemic cerebrospinal; recombinant hepatitis B vaccine for hepatitis B; Group A and C meningococcal polysaccharide vaccines to prevent epidemics; quadrivalent influenza virus split vaccine for influenza; freeze-dried human rabies vaccine to prevent rabies; adsorbed tetanus vaccine to prevent tetanus. Hualan Biological Engineering Inc. was founded in 1992 and is headquartered in Xinxiang City, the People's Republic of China.